Disarm Therapeutics has a full-time CEO—the neuro-focused biotech has signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant until February this year.
The field of biotechs developing treatments for Duchenne muscular dystrophy became more crowded this week, with biotech startup Dyne setting its sights on the muscle-wasting rare disease.
Akrevia Therapeutics is on a mission to make immunotherapies safer. The startup, based in the LabCentral incubator in Cambridge, Mass., is working on drug candidates that act much like therapies that are already on the market, including Bristol Myers-Squibb’s Yervoy and Clinigen’s Proleukin. It’s hoping it can find new drugs that mimic those effects but without sending the immune system into overdrive.
Synlogic, a developer of so-called “living medicines” comprised of engineered bacteria, is teaming up with synthetic biology company Ginkgo Bioworks in an effort to advance drug candidates to human testing more quickly.
I am the CEO of Synlogic, a synthetic biology company, where the focus of our work is the development of medicines using engineered bacteria. I love the science of what we do; it is challenging, innovative and has the potential to make a really big impact for patients. I am also challenged by issues related to organizational development; a topic of frequent discussion among CEOs.
This blog was written by Aoife Brennan, CEO of Synlogic Therapeutics, as part of the From The Trenches feature of LifeSciVC.